Drugs online research references
Akush Ginekol (Sofiia). 1990;29(6):88-90.
[Practical observations of the use of the contraceptive preparation Anteovin]
[Article in Bulgarian]
Milchev N, Pekhlivanov B, Piperkov T.
The authors describe their observations on the usage of the Hungarian biphasic contraceptive preparation Anteovin. 398 cycles of 42 women are follow-up. On the basis of the observations and subjective evaluation of the patients, the authors conclude that the preparation is well tolerated and is reliable, but is especially suitable for administration in women at the end of their reproductive period as well as in nonparous young women.
PIP: The results of the clinical trial of the biphasic contraceptive agent Anteovin (G. Richter, Hungary) are reported. The package of Anteovin consists of 11 white tablets containing 0.05 mg of ethinyl estradiol and 0.05 mg of levonorgestrel, and 10 pink tablets containing 0.05 mg of ethinyl estradiol and 0.125 mg of levonorgestrel. Preliminary clinical- pharmacological studies indicated that Anteovin did not induce atrophy of the endometrium or hyperplasia of the uterine stroma; Anteovin had favorable effect on the cervix uteri and vaginal epithelium. Anteovin was tested in 42 women aged 20 to 31 years old during a total of 398 menstrual cycles. The trial was conducted from April of 1988 to September of 1989. Of 42 women, 12 used other oral contraceptive agents, 18 used intrauterine devices, and 12 practiced coitus interruptus. Anteovin was discontinued in 2 women due to dermatitis (1) and severe nausea (1). Side-effects, which did not require discontinuation of Anteovin, were recorded in 6 women (2 had hemorrhage during the first month of Anteovin administration, 3 had nausea during two cycles, and 1 had swelling of breast). Anteovin was well-tolerated by 34 women. None of the women became pregnant.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2100964&dopt=Abstract
word match triphasil online literature
J Clin Pharmacol. 2001 Jul;41(7):723-31.
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, Graff D, Sawyer WT, Blough DK, Pieper JA.
University of Washington, Seattle, USA.
Gender-based differences in cytochrome P450 (CYP) activity may occur due to endogenous hormonal fluctuations with the menstrual cycle, which are altered by oral contraceptives. This study assessed the average activity and within-subject variability in CYP3A4 and CYP2D6 in men, women taking Triphasil, and regularly menstruating women not receiving oral contraceptives. Thirty-three healthy volunteers participated in this 28-day pilot study (12 women receiving Triphasil) (OCs), 11 regularly menstruating women not on exogenous progesterone or estrogen (no OCs), and 10 men. CYP3A4 and CYP2D6 activities were phenotyped with dextromethorphan (DM) on study days 7, 14, 21, and 28 using urinary ratios of DM:3-methoxymorphinan (3MM) and DM:dextrorphan (DX), respectively. Serial blood concentrations of estrogen and progesterone and menstrual diaries were used to determine menstrual phase in both groups of women. Average urinary DM:3MM and DM:DX in the 28 extensive metabolizers of CYP2D6 did not differ between the three study populations (p = 0.86 and 0.93, respectively). Post hoc power analysis indicated that more than 1000 subjects would be needed for 80% power (alpha = 0.05) to detect a +/- 15% difference from the population mean in the urinary ratios of dextromethorphan and its metabolites 3MM and DX. Variability in CYP3A4 and CYP2D6 activity, characterized by intrasubject standard deviation, also did not differ. The varying doses of levonorgesterol and ethinyl estradiol in Triphasil, fluctuations in estrogen and progesterone, and menstrual phase did not influence CYP3A4 or CYP2D6 activity. It was concluded that CYP3A4 and CYP2D6 activity and intrasubject variability were not different in the three study populations, and thus a clinically important difference between men, women on Triphasil, and women not receiving oral contraceptives is unlikely. High inter- and intrasubject variability in DM:3MM and DM:DX were clearly demonstrated and limit the use of dextromethorphan to phenotype endogenous CYP3A4 and CYP2D6 activity.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11452704&dopt=Abstract
word match triphasil online literature
Acta Pharm Hung. 1990 May;60(2-3):85-99.
[Clinical pharmacologic study of Tri-Regol tablets (new oral triphase contraceptives)]
[Article in Hungarian]
Farkas M, Kovacs L, Tasine Toth E.
Heves Megyei Tanacs Korhaz-Rendelointezet, Szuleszet-nogyogyaszati osztaly.
Clinical pharmacological investigations have been carried out with the new oral triphase contraceptive, Tri-RegolR. It has been established that pregnancy had not occurred during 235 cycles of 59 patients. Treatment had to be discontinued in two cases because of side effects which might have been caused by the preparation. Subjective and objective side effects occurred in 24 (10.2%) cases. During treatment with Tri-RegolR tablets proteo and steroid hormones--except prolactin--significantly decreased that phenomenon is characteristic of anovular cycle. Among patients that had previously prolonged treatment with Anteovin tablets did not occur hyperprolactinemia. Infertility would not be expected from prolonged administration of the preparation. From relative decrease of serum progesterone levels during treatment with the three preparations conclusion was drawn that the preparations did not prevent physiological conversion of endometrium.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2117333&dopt=Abstract
word match triphasil online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||